Ginkgo Bioworks Holdings Inc (DNA) 13F Holders & Ownership Data (186 Funds, Q2 2026)

DNA ranks #3184 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

DNA is a disclosed holding of Andreas Halvorsen (Viking Global Investors), one of the tracked superinvestors on AlphaSMO — it makes up 0.1% of that fund's own 13F portfolio.

186 institutions disclose a position in DNA, but none treat it as a major bet — even Anchorage Capital Group, L.L.C., its most concentrated holder, allocates just 3.8% of its own portfolio to it.

Israel Englander has added to its DNA position for two straight quarters, increasing it by $5.9M to reach $6.3M today.

Morgan Stanley has trimmed its DNA position for two straight quarters, cutting it by $4.9M while still holding $1.4M.

DNA is up 1.4% today, and institutions have been net buyers of $60.5M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

DNA reported a net loss of $290.8M over the trailing twelve months.

• Not yet profitable — net loss of $290.8M over the trailing twelve months
• Revenue declined 46.8% year over year
• Net income improved year over year, from -$315.2M to -$290.8M
• Operating cash flow was negative, using $171.1M in cash
• Current ratio of 4.92x — enough short-term assets to cover short-term liabilities
• Liabilities run 1.20x equity — within a conventional range